WHAT’S NEW IN SCLC?
ASSESSING EMERGING THERAPEUTIC OPTIONS

MONDAY, OCTOBER 16, 2017
REGISTRATION/BREAKFAST: 6:30 AM – 7:00 AM | PROGRAM: 7:00 AM – 8:00 AM
VENUE: PACIFICO YOKOHAMA CONVENTION CENTER | ROOM: ANNEX HALL, F203/204

MODERATOR
Charles Rudin, MD, PhD
Chief
Thoracic Oncology Service
Sylvia Hassenfeld Chair in Lung Cancer Research
Co-Director
Drukenmiller Center for Lung Cancer Research
Professor of Medicine
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, New York

PANELISTS
Jeffrey Crawford, MD
Professor
Duke Cancer Institute
Durham, North Carolina

Enriqueta Felip, MD, PhD
Head
Thoracic Oncology Unit
Vall d’Hebron University Hospital
Barcelona, Spain

Antonio Rossi, MD
Medical Oncologist
Division of Medical Oncology
S.G. Moscati Hospital
Avellino, Italy

To register, please visit:
www.medscape.org/townhall/sclc-new-therapies

This activity is supported by an independent educational grant from AbbVie.
**ACTIVITY OVERVIEW**

Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers. However, SCLC is much more aggressive and difficult to treat than other forms of lung cancer, and the global incidence of SCLC is predicted to increase over the next decade. Recent developments are providing hope that outcomes for SCLC can be improved, including significant changes in how subtypes of SCLC are defined. In this symposium, an international panel of lung cancer oncologists will discuss new diagnostic and therapeutic options and their potential integration into physicians’ daily practice.

**TARGET AUDIENCE**

This activity is intended for oncologists, pulmonologists, and pathologists.

**LEARNING OBJECTIVES**

Upon completion of this activity, participants will:
- Have increased knowledge regarding the
  - Outstanding unmet treatment needs of patients with SCLC
  - Rationale underpinning emerging biological targets in late stage trials for SCLC
  - Preclinical and current clinical evidence supporting the development of new therapeutics in SCLC

**GOAL STATEMENT**

The goal of this activity is to update clinicians on emerging diagnostic and therapeutic options for patients with SCLC and discuss the rationale and supporting evidence for new approaches to integrate recent advances into physicians’ daily practice.

**ACCREDITATION STATEMENT**

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**For Physicians**

Medscape, LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To register, please visit: [www.medscape.org/townhall/sclc-new-therapies](http://www.medscape.org/townhall/sclc-new-therapies)